Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. Results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leukemia
Главные авторы: Matulis, Shannon M., Gupta, Vikas A., Nooka, Ajay K., Von Hollen, Hayley, Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874660/
https://ncbi.nlm.nih.gov/pubmed/26707935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.350
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы